BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lovastatin
,
rs2300478
,
PPARA
,
Fatty acid metabolic process
,
Obesity
,
Stem cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
new inhibitors
Summary
General Info
Curated Studies
Most Correlated Studies
Liver Pharmacology and Xenobiotic Response Repertoire
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
B-cell lymphoma cell lines treated by 92 FDA approved compounds - a timecourse
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Non-small cell lung cancer HCC515 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
Oligopeptides as full-length New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors.
Simplified captopril analogues as NDM-1 inhibitors.
Diaryl-substituted azolylthioacetamides: Inhibitor discovery of New Delhi metallo-β-lactamase-1 (NDM…
Inhibitor and substrate binding by New Delhi metallo-beta-lactamase-1: a molecular dynamics studies.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients Wi…
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have …
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ